|
Active Clinical TrialsBelow is a listing of the current treatment clinical trials for cancer offered through Hematology-Oncology Associates. Our available trials are listed by site of involvement. For a complete description of a particular clinical trial, go to the CancerTrials search page. You may either enter the protocol number in the simple search or use the focused search by filling in the fields of information. Once this information is entered click on the search button at the bottom of the page. You will then get a page listing the trial by title. Either select the trial using the check box, and click on the "display selected studies" button or click on the title and the entire trial will be available to read and print out as you wish. BreastCALGB 79809: Phase III Trial of Intravenous Zoledronic Acid in the Prevention of Bone Loss in localized Breast Cancer Patients with Chemotherapy-Induced Ovarian Failure. CALGB 40101: Cyclophosphamide and Doxorubicin (CA 4 vs 6 Cycles) vs. Paclitaxel (12 vs. 18 weeks) as Adjuvant Therapy for Women with Node Negative Breast Cancer. CALGB 40105: Evaluation of Novel Therapeutic Agents (Celecoxib) Against Breast Cancer : An Innovative Randomized Phase II Trial Design. CALGB 49907: A Randomized Trial of Adjuvant Chemotherapy with Standard Regimens, Cytoxan/Methotrexate/5-FU or Adriamycin/Cytoxan vs. Xeloda in Women 65 years or Older with Node Positive or High Risk Node Negative Breast Cancer . CALGB 49909: Phase III Study of Adriamycin/Cytoxan Followed by Weekly Taxol With or Without Herceptin as Adjuvant Treatment for Women With HER2/NEU +, Node-Positive Breast Cancer. CTSU S0012: Randomized Comparison of Standard Doxorubicin plus Cyclophosphamide vs. Weekly Doxorubicin and Daily Oral Cyclophosphamide plus G-CSF as Neoadjuvant Therapy for Inflammatory and Estrogen Negative Locally Advanced Breast Cancer, Phase III. **Trial available through CTSU SWOG S0221: Phase III Trial of Continuous Schedule AC + G vs. Q 2 Week Schedule AC, Followed by Paclitaxel Given Either Every 2 Weeks or Weekly for 12 Weeks as Post-Operative Adjuvant Therapy in Node-Positive or High-Risk Node Negative Breast Cancer. S0026: Phase III Randomized Trial of Anastrozole Versus Anastrozole and Fulvestrant as First Line Therapy for Post Menopausal Women with Metastatic Breast Cancer NSABP B-35: A Clinical Trial Comparing Anastrazole with Tamoxifen in Postmenopausal Patients With DCIS Undergoing Lumpectomy with Radiation Therapy. NSABP B-36: A Clinical Trial of Adjuvant Therapy Comparing Six Cycles of 5-Fluorouracil, Epirubicin and Cyclophosphamide (FEC) to Four Cycles of Adriamycin and Cyclophosphamide (AC), With or Without Celecoxib, in Patients With Node-Negative Breast Cancer NCIC MA.21 : Randomized Trial Comparing 3 Combinations of Chemotherapy: EC ( E pirubicin, C yclophosphamide) + Epoetin Alfa Followed by Paclitaxel vs. AC ( A driamytin, C yclophosphamide) Followed by Paclitaxel vs CEF ( C yclophosphamide, E pirubicin and 5- F luorouracil in Premenopausal and Early Postmenopausal Women Who Have Had Surgery for Axillary Node Positive or High Risk Node Negative Breast Cancer. NCIC MA.27: Phase III Randomized Trial of Exemestane vs. Anastrozole With or Without Celecoxib in Post-Menopausal Women with Receptor Positive Breast Primary Cancer. GSK EGF 30008: A Randomized, Double Blind, Placebo-Controlled, Multicenter Phase III Study Comparing GW572016 and Letrozole vs. Letrozole in Subjects with Estrogen/Progesterone Receptor-Positive Advanced or Metastatic Breast Cancer. GynecologicalGOG 0209: Randomized Phase III Trial of Doxorubicin/Cisplatin/Paclitaxel and GCSF vs. Carboplatin/Paclitaxel in Patients With Stage III & IV or Recurrent Endometrial Cancer. GOG 0198: A Randomized Study of Tamoxifen vs. thalidomide in Patients with Biochemical Recurrence Only Epithelial Ovarian Cancer , Cancer of the Fallopian Tube, and Primary Peritoneal Carcinoma After 1 st line Chemotherapy. S0200: A Phase III Randomized Study of Pegylated Liposomal Doxorubicin Plus Carboplatin Versus Carboplatin in Platinum-Sensitive Patients with Recurrent Epithelial Ovarian or Peritoneal Carcinoma. GastrointestinalN0147 : A Randomized Phase III Trial of Irinotecan (CPT-11) and/or Oxaliplatin (OXAL) Plus 5-Fluorouracil (5-FU)/Leucovorin (CF)With or Without Cetuximab (C225) after Curative Resection for Patients with Stage III Colon Cancer CALGB 80203: A Phase III Trial of Irinotecan/5-FU/Leucovorin or Oxaliplatin/5-FU/Leucovorin With and Without Cetuximab (C225) For Patients with Untreated Metastatic Adenocarcinoma of the Colon or Rectum. E3201: Intergroup Randomized Phase III Study of Postoperative Irinotecan, 5-Fluorouracil and Leucovorin vs. Oxaliplatin, 5-Fluorouracil and Leucovorin vs. 5-Fluorouracil and Leucovorin for Patients with Stage II or III Rectal Cancer Receiving Either Preoperative Radiation and 5-Fluorouracil or Postoperative Radiation and 5-Fluorouracil. NSABP C-08 : A Phase III Clinical Trial Comparing Infusional 5-Fluorouracil (5-FU), Leucovorin, and Oxaliplatin (mFOLFOX6) Every Two Weeks with Bevacizumab to the Same Regimen Without Bevacizumab for the Treatment of Patients With Resected Stages II and III Carcinoma of the Colon NSABP R-04: Treatment With Two Chemotherpay Drugs Combined With Radiation Therapy For Patients With Rectal Cancer CALGB 80101: Phase III Intergroup trial of Adjuvant Chemoradiation After Resection of Gastric or Gastroesophageal Adenocarcinoma. CALGB 89903: Sequential Phase II Study of Anti-Idiotype Monoclonal Antibody Vaccines CeaVac and TriAb in Patients with Minimal Metastatic Colorectal Cancer. ACOSOG Z9001: A Phase III Randomized Double-Blind Study of Adjuvant ST1571 (Gleevac) vs. Placebo in Patients Following the Resection of Primary Gastrointestinal Stromal Tumor. ProstateJPR. 7: Phase III Randomized Trial Comparing Intermittent vs. Continuous Androgen Suppression for Patients with PSA Progression in the Clinical Absence of Distant Mets. Following Radiotherapy for Prostate Cancer. MDA 3410: A Prospective Randomized Phase III Trial Comparing Consolidation Therapy With or Without Strontium-89 Following Induction Chemotherapy in Androgen-Independent Prostate Cancer.
SeminomaThere are no active trials at this time. PancreaticE6201: Phase III, Randomized Study of Gemcitabine (fixed dose rate infusion) and Oxaliplatin versus Gemcitabine (fixed dose rate infusion) versus Gemcitabine (30 minute infusion) in Pancreatic Carcinoma. Locally advanced or metastatic. CALGB 80003: Phase II Trial of Gemcitabine, 5-FU and Radiation Therapy in Locally Advanced Non-Metastatic Pancreatic Adenocarcinoma . E4201: A Randomized Phase III Study of Gemcitabine in Combination with Radiation Therapy vs Gemcitabine Alone in Patients with Localized, Unresectable, Pancreatic Cancer. CALGB 80303: A Randomized Phase III Trial of Gemcitabine plus Bevacizumab (NSC#704865) versus Gemcitabine plus Placebo in Patients with Advanced Pancreatic Cancer SWOG S0205: A Phase III, Randomized Open-Label Study Comparing Gemcitabine Plus Cetuximab (IMC-C225) Versus Gemcitabine as First-Line Therapy of Patients With Advanced Pancreatic LungE3598 : A Phase III Trial of Carboplatin, Paclitaxel, and Thoracic Radiotherapy, with or without Thalidomide, in Patients with Stage III Non Small Cell Lung Cancer S0023: Phase III Trial of Cisplatin/Etoposide/Radiotherapy with Consolidation Docetaxel Followed by Maintenance Therapy with ZD1839 or Placebo in Patients with Inoperable Locally Advanced Stage III Non-Small Cell Lung Cancer. S0124: Randomized Phase III Trial of Cisplatin and Irnotecan vs. Cisplatin and Etoposide in Patients with Extensive Stage Small Cell Lung Cancer. CALGB 30303: A Phase II Randomized Study of Dose-Dense Docetaxel and Cisplatin Every Two Weeks with Pegfilgrastim and Darbepoetin Alfa with and without the Chemoprotector BNP7787 in Patients with Advanced Non-small Cell Lung Cancer RCCQC 30201 : Phase II Trial of Topotecan as Second Line Therapy for Small Cell Lung Cancer . NCIC BR.19: A Phase III Prospective Randomized, Double-Blind, Placebo-Controlled Trial of the Epidermal Growth Factor Receptor Antagonist, ZD1839 (IRESSA) in Completely Resected Primary Stage IB, II and IIIA Non-Small Cell Lung Cancer. CALGB 30107: Phase II Study of PTK787/ZK222584 (NSC #719335, IND #66370) in Patients with Unresectable Malignant Mesothelioma back to top Head & NeckCTSU E1302: Phase III Randomized, Placebo-Controlled, Trial of Docetaxel Versus Docetaxel Plus ZD1839 (Iressa, ZD1839 (Iressa, gefitinib)) in Performance Status 2 or Previously Treated Patients With Recurrent or Metastatic Head and Neck Cancer Renal/BladderCALGB 90101: Phase II Trial of Herceptin in Patients with Previously Treated Advanced Urothelial Tract Transitional Cell Carcinoma. CALGB 90102: A Phase II Study of Cisplatin, Gemcitabine, and ZD1839 For the Treatment of Advanced Urothelial Tract Carcinoma. CALGB 90206: A Randomized Phase III Trial of Interferon alfa-2b or Interferon alfa-2b plus Bevacizumab in Patients with Advanced Renal Carcinoma . CALGB 90207: Phase II trail of PS-341 in Patients with Previously Treated Advanced Urothelial Tract Transitional Cell Carcinoma. CALGB 90104: A Randomized Phase III Study Comparing Sequential Chemotherapy(AG-T) to Cisplatin and Gemcitabine (GC) As Adjuvant Treatment After Cystectomy For Transitional Cell Carcinoma of the Bladder. LymphomaCTSU E4402: Randomized Phase III Trial Comparing Two Different Rituximab Dosing Regimens for Patients with Low Tumor Burden Indolent Non-Hodgkin's Lymphoma . LeukemiaSWOG S0106: A Phase III Study of the Addition of Gemtuzumab Ozogamicin (Mylotarg ®) During Induction Therapy Versus Standard Induction With Daunomycin and Cytosine Arabinoside Followed by Consolidation and Subsequent Randomization to Post-Consolidation Therapy With Gemtuzumab Ozogamicin (Mylotarg ®) or No Additional Therapy for Patients Under Age 56 With Previously Untreated De Novo Acute Myeloid Leukemia (AML) CALGB 10002: Phase II Study of Rituxan and Short Duration High Intensity Chemotherapy with G-CSF Support in Previously Untreated Patients with Burkitt Lymphoma/Leukemia Multiple MyelomaThere are no active trials at this time MelanomaCALGB 500002: Phase III Trial of High Dose Interferon Alpha-2b Versus Cisplatin, Vinblastine, DTIC Plus IL-2 in Patients with High Risk Melanoma. CALGB 500103: Phase III Randomized Study for Four Weeks of High Dose IFN alpha- 2b in Stage T3-T4 or N1 (microscopic) Melanoma.
Myelodysplastic SyndromeNo active trials at this time
Page last updated September 28, 2004 |
|||
